Delivery Order SPE2DB20D7061-SPE2DB25FSPA1
- Not listed
- The Defense Logistics Agency awarded a $5,239.40 delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Omnipaque 300 mg/ml in 100ml infusion bottles. This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 15, 2025. The contract is performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $1,622.85 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for Omnipaque 300 mg/ml infusion bottles (100ml units). The contract, which is non-set-aside and competitively awarded, is scheduled for completion by August 5, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,200 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of OMNIPAQUE 240 mg/ml vials in 10 ml quantities. This is a firm fixed price, non-set-aside contract with a completion date of July 30, 2025, and performance location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), a $999.999 billion agreement...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 8, 2025, for the supply of Omnipaque 240 mg/ml vials (10 ml units) at a ceiling value of $1,200.00. This firm fixed-price delivery order, which is not set-aside, is scheduled for completion by August 11, 2025, and will be performed at the awardee's location in Conshohocken, Pennsylvania. The contract represents a routine pharmaceutical procurement supporting federal medical supply needs...
- The Defense Logistics Agency awarded a delivery order valued at $2,282.49 to AmerisourceBergen Drug Corp for the supply of Omnipaque 300 mg/mL in 100 mL infusion bottles. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, with performance based in Conshohocken, Pennsylvania, and an ultimate completion date of September 10, 2025. This delivery order represents a task issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a $1,582.41 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Omnipaque 180 mg/mL vials (10 mL units) on August 20, 2025, with a completion date of August 21, 2025. This non-set-aside competitive award will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999.00...
- The Defense Logistics Agency awarded a $1,306.43 firm fixed price delivery order to AmerisourceBergen Drug Corp for OMNIPAQUE 300 mg/mL vials (10 mL units) on September 2, 2025, with an ultimate completion date of September 3, 2025. This non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 and extending through December 2026. The product will be performed at...
- The Defense Logistics Agency awarded a delivery order valued at $7,504.83 to AmerisourceBergen Drug Corp for the supply of Omnipaque 300 mg/mL infusion bottles (100 mL units). This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by July 24, 2025. AmerisourceBergen Drug Corp will perform the delivery from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract action...
- The Defense Logistics Agency awarded a delivery order valued at $3,381.60 to AmerisourceBergen Drug Corp for the supply of Omnipaque 350 mg/ml, a contrast media pharmaceutical product in 500ml Pluspak packaging. This firm fixed-price delivery order, awarded on July 24, 2025, represents a non-competitive, non-set-aside procurement with an ultimate completion date of July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company...
- This is a $6,378.55 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the supply of OMNIPAQUE 350 MG/ML PLUSPAK 500ML, a medical product, with a period of performance through June 17, 2024. This order is part of AmerisourceBergen's $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for...
- SPE2DB20D7061Indefinite Delivery Contract
- SPE2DB20D7061-SPE2DB25FSPA1Delivery Order
The Defense Logistics Agency awarded a $1,673.00 delivery order to AmerisourceBergen Drug Corp for OMNIPAQUE 350 mg/mL infusion bottles (150 mL) on July 24, 2025, with completion scheduled for July 25, 2025. This non-set-aside, competitively awarded contract represents a firm fixed price delivery order for pharmaceutical supplies to be performed at the awardee's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, leverages this prime indefinite delivery vehicle to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. The company's contract portfolio demonstrates significant federal procurement capability across multiple therapeutic domains, with consistent delivery of brand-name and generic medications, vaccines, and specialized medical supplies through competitively awarded transactions. The DLA's Pharmaceutical Prime Vendor Global Program Generation V initiative is expected to expand vendor diversity through multiple regional awards, positioning AmerisourceBergen as a critical supplier within the federal medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 7/24/25 |